Citigroup cuts target to USD 320 for Alnylam Pharmaceuticals stock
Published on 10/15/2026 at 21:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and earnings date
- On October 14, 2026, Citigroup lowered its Alnylam target from USD 340.00 to USD 320.00.
- Revenue reached USD 1.29 billion in the second quarter of 2026.
- Alnylam Pharmaceuticals stock costs EUR 207.45 at Lang & Schwarz on October 15, 2026 at 9:36 p.m. CEST, up 3.58 percent on Nasdaq versus the close of October 14, 2026.
- Alnylam will report third-quarter 2026 results on October 29, 2026, before U.S. markets open.
Citigroup lowered its Alnylam Pharmaceuticals price target from USD 340.00 to USD 320.00 on October 14, 2026, while maintaining a Buy rating, according to MarketBeat. The USD 320.00 target is 37.63 percent above the Nasdaq price of USD 232.51 at the latest quoted session point. Alnylam Pharmaceuticals stock was trading at EUR 207.45 at Lang & Schwarz on October 15, 2026 at 9:36 p.m. CEST.
Revenue reached USD 1.29 billion
Alnylam reported USD 1.29 billion in revenue for the second quarter of 2026, according to Yahoo Finance. The same period included USD 164.49 million in net income attributable to common shareholders, according to the standardized quarterly figures for the period ended June 30, 2026.
Stock stays above its yearly low
The Nasdaq price of USD 232.51 on October 15, 2026 stood USD 34.70, or 17.54 percent, above the 52-week low of USD 197.81. It was 53.08 percent below the 52-week high of USD 495.55. Trading volume was 895,986 shares against an average of 1,723,951 shares, a 48.03 percent shortfall.
Valuation and the next reporting date
Alnylam had a market capitalization of USD 31.1 billion and a trailing P/E ratio of 39.27 as of October 15, 2026. The company will report third-quarter 2026 results on October 29, 2026, before U.S. markets open, with a conference call at 8:30 a.m. ET, according to BioSpace.
Comparison with peers
Alnylam Pharmaceuticals (Nasdaq, USD, October 15, 2026): plus 3.58 percent, P/E 39.27, market capitalization USD 31.1 billion
Ionis Pharmaceuticals (Nasdaq, USD, October 15, 2026): plus 3.43 percent, P/E minus 12.75, market capitalization USD 7.3 billion
Repligen (Nasdaq, USD, October 15, 2026): plus 4.25 percent, P/E 254.36, market capitalization USD 11.8 billion
Euro quote after the Xetra close
The Lang & Schwarz quote was EUR 207.45 on October 15, 2026 at 9:36 p.m. CEST. On Nasdaq, Alnylam was at USD 232.51 at 3:39 p.m. EDT, up 3.58 percent versus the October 14, 2026 close.
The further course of trading is shown by the continuously updated real-time quote of Alnylam Pharmaceuticals stock.
Alnylam Pharmaceuticals market data
- Company: Alnylam Pharmaceuticals, Inc.
- ISIN: US02043Q1076
- Ticker: ALNY
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 15, 2026, 9:36 p.m. CEST): EUR 207.45
- Change on Nasdaq versus October 14, 2026: plus 3.58 percent
- Market capitalization: USD 31.1 billion (as of October 15, 2026)
- 52-week range: USD 197.81-495.55 (as of October 15, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: October 29, 2026
Market context: Market report Nasdaq Composite.
